Acquisition of Omaveloxolone

This tender concerns the acquisition of Omaveloxolone. Omaveloxolone is a drug used in the treatment of certain medical conditions. The specific details regarding the quantity, dosage, and intended use of Omaveloxolone are expected to be outlined in the full tender documentation. This procurement is likely aimed at fulfilling a specific medical need within a healthcare facility or for a public health program. Potential bidders are expected to be suppliers or manufacturers capable of providing pharmaceutical products that meet stringent quality and regulatory standards. Further information regarding the tender process, including submission deadlines, eligibility criteria, and evaluation procedures, would be available in the official tender announcement. The objective is to secure a reliable supply of this pharmaceutical agent to ensure continuity of care or to meet specific treatment protocols. The tender process will likely involve a competitive bidding system to ensure value for money and adherence to procurement regulations.

This is a supplies contract in the health and medical services, Monitoring Evaluation and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 487,200.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.